Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR-ICR / Cancer Research Society Partnership - Res. Gr. Cancer Prev.

McGill University

$67,500.00

Does E-cigarette Use Enhance Lung Tumor Formation?

FY 2024-25

Summary
Background: E-cigarettes were originally developed as a smoking-cessation tool. E-cigarettes came onto the North American market in 2007 and have exploded in popularity, particularly amongst youth and young adults who have never smoked cigarettes. Canada now has one of the highest youth vaping rates in the world. The newness of e-cigarettes, prevalent use by younger individuals and the fact that diseases, such as cancer, most often appear in people over the age of 40 means that the overall health consequences of e-cigarette use are unknown. Vaping is the act of inhaling into the lungs the vapor or aerosol that is produced by an e-cigarette. It is designed to simulate the act of smoking but without tobacco combustion. E-cigarettes consist of a rechargeable battery, an atomizer (or heating element/coil) and a liquid (e-liquid) that contains a solvent (usually propylene glycol [PG] and vegetable glycerin [VG]), nicotine and various additives including flavors, of which there are thousands. Most chemicals used in eliquids have never been safety-tested for inhalation. Alarmingly, heating the e-liquid generates an aerosol that is now known to contain nicotine derivatives, heavy metals (cobalt, arsenic, cadmium, chromium, and nickel) and other chemicals (asbestos, acrolein, and formaldehyde) that are strongly associated with the development of cancer. In line with this, there are also studies reporting that e-cigarette aerosols inhibit DNA repair mechanisms and induce oxidative DNA damage in the lungs and other organs, but results are conflicting, which may reflect the diversity of products on the market and/or choice of model. Of note, in our hands, ecigarette exposure for 4 months increases DNA damage in the lung by 4-5x. Our solution: We propose to use our established preclinical mouse model of e-cigarette exposure to provide insight into the potential pathological consequences of vaping, as this model replicates human e-cigarette use patterns. Using this model, we found that even a one-month daily exposure induced significant changes in signaling pathways in the lung in a sex-dependent manner. Many of the pathways were related to oxidative metabolism by cytochrome P450 enzymes, which are known to transform pro-carcinogens into reactive metabolites that can bind DNA and lead to cancer formation. Therefore, we will now utilize our inhalation exposure in a model of oncogene-induced lung tumor formation to ask whether e-cigarette aerosol inhalation during youth leads to indices of lung cancer. Approach: We propose to test the hypothesis that vaping increases lung tumor formation in KRASLSL-G12D mice bearing a loxPSTOP- LoxP (LSL)-KRAS G12D allele, which is conditionally activated in the lungs by intratracheal administration of viral vectors expressing CRE recombinase and shRNA for TP53. We have chosen this model because these mice exhibit lung adenocarcinoma formation as early as 7 weeks with endpoint reached within 40 weeks, a sufficiently long latency to capture acquired mutational burden from vaping exposure. We will test whether vaping alters lung tumor formation over time in these mice. Mice will be exposed daily to room air or to popular commercial e-cigarettes. We will assess tumor growth, the immune component of the lung tumor microenvironment by flow cytometry, and cellular heterogeneity within the lung. We will determine the mutational spectrum of sorted tumor cells to determine whether recurrent DNA changes are observed following vaping exposure. Impact: We predict that vaping will accelerate lung tumorigenesis in these mice, potentially with a bias towards male mice. These experiments therefore have the potential to define biomarkers or DNA mutational signatures associated with vaping-induced tumors. Together, these experiments could provide valuable information to regulatory bodies, who are assessing the risk of ecigarette use.
Program
CIHR-ICR / Cancer Research Society Partnership - Res. Gr. Cancer Prev.
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
539244
Name
Mann Koren K
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Does E-cigarette Use Enhance Lung Tumor Formation?
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
CIHR-ICR / Cancer Research Society Partnership - Res. Gr. Cancer Prev.
Keyworddelim
Cancer
Abstract
Background: E-cigarettes were originally developed as a smoking-cessation tool. E-cigarettes came onto the North American market in 2007 and have exploded in popularity, particularly amongst youth and young adults who have never smoked cigarettes. Canada now has one of the highest youth vaping rates in the world. The newness of e-cigarettes, prevalent use by younger individuals and the fact that diseases, such as cancer, most often appear in people over the age of 40 means that the overall health consequences of e-cigarette use are unknown. Vaping is the act of inhaling into the lungs the vapor or aerosol that is produced by an e-cigarette. It is designed to simulate the act of smoking but without tobacco combustion. E-cigarettes consist of a rechargeable battery, an atomizer (or heating element/coil) and a liquid (e-liquid) that contains a solvent (usually propylene glycol [PG] and vegetable glycerin [VG]), nicotine and various additives including flavors, of which there are thousands. Most chemicals used in eliquids have never been safety-tested for inhalation. Alarmingly, heating the e-liquid generates an aerosol that is now known to contain nicotine derivatives, heavy metals (cobalt, arsenic, cadmium, chromium, and nickel) and other chemicals (asbestos, acrolein, and formaldehyde) that are strongly associated with the development of cancer. In line with this, there are also studies reporting that e-cigarette aerosols inhibit DNA repair mechanisms and induce oxidative DNA damage in the lungs and other organs, but results are conflicting, which may reflect the diversity of products on the market and/or choice of model. Of note, in our hands, ecigarette exposure for 4 months increases DNA damage in the lung by 4-5x. Our solution: We propose to use our established preclinical mouse model of e-cigarette exposure to provide insight into the potential pathological consequences of vaping, as this model replicates human e-cigarette use patterns. Using this model, we found that even a one-month daily exposure induced significant changes in signaling pathways in the lung in a sex-dependent manner. Many of the pathways were related to oxidative metabolism by cytochrome P450 enzymes, which are known to transform pro-carcinogens into reactive metabolites that can bind DNA and lead to cancer formation. Therefore, we will now utilize our inhalation exposure in a model of oncogene-induced lung tumor formation to ask whether e-cigarette aerosol inhalation during youth leads to indices of lung cancer. Approach: We propose to test the hypothesis that vaping increases lung tumor formation in KRASLSL-G12D mice bearing a loxPSTOP- LoxP (LSL)-KRAS G12D allele, which is conditionally activated in the lungs by intratracheal administration of viral vectors expressing CRE recombinase and shRNA for TP53. We have chosen this model because these mice exhibit lung adenocarcinoma formation as early as 7 weeks with endpoint reached within 40 weeks, a sufficiently long latency to capture acquired mutational burden from vaping exposure. We will test whether vaping alters lung tumor formation over time in these mice. Mice will be exposed daily to room air or to popular commercial e-cigarettes. We will assess tumor growth, the immune component of the lung tumor microenvironment by flow cytometry, and cellular heterogeneity within the lung. We will determine the mutational spectrum of sorted tumor cells to determine whether recurrent DNA changes are observed following vaping exposure. Impact: We predict that vaping will accelerate lung tumorigenesis in these mice, potentially with a bias towards male mice. These experiments therefore have the potential to define biomarkers or DNA mutational signatures associated with vaping-induced tumors. Together, these experiments could provide valuable information to regulatory bodies, who are assessing the risk of ecigarette use.
Competitiondate
202502
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mann, Koren K
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $67,500~ $0~